SmithKline Famvir Herpes Latency And Hepatitis B Indications In Phase III
Executive Summary
SmithKline Beecham's antiviral Famvir is in Phase III trials for prevention of genital herpes latency, SB Senior VP-Anti-infectives Research Marty Rosenberg, PhD, told an analysts briefing April 14 in New York City.